Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.

The key factors shaping China’s biopharma boom

Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

Vaccine makers face mRNA backlash as states seek further restrictions

A handful of states are targeting the technology at the same time the Trump administration is cutting research funding and revoking vaccine contracts.

How non-traditional investors fuel up-and-coming biotechs when VC funding dries up

Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.

Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do

Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.